# This mutation (found in the lambda VOC) causes a 4.4x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. However, this did not impact the susceptability to Nirmatrelvir.
# FDA (2021) https://www.fda.gov/media/155050/download
G15S

# This mutation causes a 3.5x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
T135I

# This mutation causes a 91.9x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
S144A

# This mutation causes a 6.4x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
H164N

# This mutation causes a 233x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
H172Y

# This mutation causes a 65.4x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
Q189K

# This mutation causes a 3.7x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
D248E

# This mutation causes a 23.6x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
 Y54A

# This mutation causes a 3.7x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download


# This mutation causes a 3.7x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
